Tumor localization of 16β-18F-fluoro-5α- dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer

Journal of Nuclear Medicine

Volumn 45, Issue 3, 2004, Pages 366-373

  Larson, Steven M ^a   Morris, Michael ^a   Gunther, Ilonka ^a   Beattie, Brad ^a   Humm, John L ^a   Akhurst, Timothy A ^a   Finn, Ronald D ^a   Erdi, Yusuf ^a   Pentlow, Keith ^a   Dyke, Jon ^a   Squire, Olivia ^a   Bornmann, William ^a   McCarthy, Timothy ^b   Welch, Michael ^b   Scher, Howard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

16 18F fluoro 5 dihydrotestosterone; Androgen receptor; PET; Prostate cancer

Indexed keywords

16BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; 17 ALLYAMNO 17 DEMETHOXYGELDANAMYCIN; CELECOXIB; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GELDANAMYCIN; GOSERELIN; LEUPRORELIN; PAMIDRONIC ACID; TESTOSTERONE; UNCLASSIFIED DRUG; 11 FLUORO DIHYDRO TESTOSTERONE; 11-FLUORO-DIHYDRO-TESTOSTERONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR LOCALIZATION; BONE TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLIC CLEARANCE RATE; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; VALIDATION STUDY; WHOLE BODY COUNTING;

AGED; BONE NEOPLASMS; DIHYDROTESTOSTERONE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, ANDROGEN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING;

EID: 2342599027     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer Statistics, 2003. Cancer J Clin. 2003;53:5-26.
2. Horst T, Meyer B, Taplin S. Screening, health promotion, and prevention in men. Prim Care. 1995;22:679-695.
3. Fenton MA, Shuster TD, Fertig AM, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res. 1997;3:1383-1388.
4. Craft N, Sawyers CL. Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev. 1998;17:421-427.
5. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;94:401-406.
6. Koivisto P, Visakorpi T, Rantala I, et al. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol. 1997;183:51-56.
7. Agus DB, Cordon-Cardo C, Fox W, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999;91:1869-1876.
8. Bonasera TA, O'Neil JP, Xu M, et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med. 1996;37:1009-1015.
9. 18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution. J Med Chem. 1995;38:816-825.
10. Degrado TR, Turkington TG, Williams JJ. Performance characteristics of a whole-body PET scanner. J Nucl Med. 1994;34:1348-1406.
11. Liu A, Dence C, Welch MJ. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med. 1992;33:724-734.
12. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002;8:986-993.
13. Larson, SM, Schwartz LH. Advances in imaging. Semin Oncol. 1994;21:598-606.
14. Smith PH, Bono A, Calais da Silva F. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer: a subanalysis of EORTC trial 30853 - the EORTC Urological Group. Cancer. 1990;6:1009-1016.
15. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996;99:751-756.
16. 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg. 1999;78:282-287.
17. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;43:254-261.
18. Scher HI. Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer. 2003;7(3 suppl):758-771.
19. Scher HI, Kelly WK. States and state transitions are all that really matter [editorial]. J Urol. 2002;168:2451-2453.
20. Yeh SDJ, Larson SM, Garza D, et al. Detection of bony metastases of androgen independent prostate cancer by PET-FDG. Nucl Med Biol. 1996;23:693-697.